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ABSTRACT
G1P[8] rotaviruses are responsible for the majority of human rotavirus infections
worldwide. The effect of universal mass vaccination with rotavirus vaccines on
circulating G1P[8] rotaviruses is still poorly understood. Therefore we analyzed the
complete genomes of the RotarixTM vaccine strain, and 70 G1P[8] rotaviruses,
detected between 1999 and 2010 in Belgium (36 before and 34 after vaccine
introduction) to investigate the impact of rotavirus vaccine introduction on
circulating G1P[8] strains. All rotaviruses possessed a complete Wa-like genotype
constellation, but frequent intra-genogroup reassortments were observed as well as
multiple different cluster constellations circulating in a single season. In addition,
identical cluster constellations were found to circulate persistently over multiple
seasons. The RotarixTM vaccine strain possessed a unique cluster constellation that
was not present in currently circulating G1P[8] strains. At the nucleotide level, the
VP6, VP2 and NSP2 gene segments of RotarixTM were relatively distantly related
to any Belgian G1P[8] strain, but other gene segments of RotarixTM were found in
clusters also containing circulating Belgian strains. At the amino acid level, the genetic
distance between RotarixTM and circulating Belgian strains was considerably lower,
except for NSP1. When we compared the Belgian G1P[8] strains collected before and
after vaccine introduction a reduction in the proportion of strains that were found in
the same cluster as the RotarixTM vaccine strain was observed for most gene segments.
The reduction in the proportion of strains belonging to the same cluster may be the
result of the vaccine introduction, although natural fluctuations cannot be ruled out.
Subjects Virology, Gastroenterology and Hepatology, Infectious Diseases
Keywords Rotaviruses, Wa-like, G1P[8], Genetic diversity, Vaccine introduction
INTRODUCTION
Rotavirus A (RVA) is the most important etiological agent for diarrhea in children under
5 years of age worldwide (Tate et al., 2012). The eleven-segmented double stranded RNA
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genome allows rotaviruses to reassort frequently and aides to establish new variants of
genes in the human RVA population. Rotaviruses are classified according to their outer
capsid proteins VP7 and VP4, which determine the G- and P-genotype, respectively. In
humans, the most common genotypes are G1P[8], G2P[4], G3P[8], G4P[8], G9P[8] and
G12P[8] (Bányai et al., 2012). An extension of this dual classification system comprises
all eleven segments and revealed the existence of two major genotype constellations
in humans, often referred as Wa-like and DS-1-like (Matthijnssens et al., 2008). P[8]
genotypes are commonly associated with a Wa-like genotype constellation (e.g., G1-P[8]-
I1-R1-C1-M1-A1-N1-T1-E1-H1) and P[4] genotypes are commonly associated with a
DS-1-like genotype constellation (e.g., G2-P[4]-I2-R2-C2-M2-A2-N2-T2-E2-H2). In
humans, the Wa-like genotype constellation is the most important and over 90% of all
infections are caused by rotaviruses belonging to this genotype constellation (Bányai et al.,
2012;Matthijnssens & Van Ranst, 2012).
Within the Wa-like genogroup, G1P[8] genotypes are the most prevalent worldwide,
although regional and temporal variations are common (Bányai et al., 2012). Therefore,
one of the currently available rotavirus vaccines, RotarixTM, contains a live attenuated
G1P[8] rotavirus. RotarixTM has been available for use in Belgium since June 2006 and
a very high coverage of approximately 90% was reached within months after vaccine
introduction (Zeller et al., 2010). RotaTeqTM has been available in Belgium since June
2007 and is used less frequently (approximately 15% of all administered rotavirus vaccines
is RotaTeqTM) (Zeller et al., 2010;Matthijnssens et al., 2014). The genotype distribution
of rotaviruses detected at the Gasthuisberg university hospital in Leuven has been studied
since the 1999–2000 rotavirus season. During this period G1P[8] strains were detected
in every season, although the prevalence of G1P[8] strains varied widely (Zeller et al.,
2010). The genetic variability within the human G1 and P[8] genotypes is relatively large,
especially when compared to other human genotypes and multiple G1 and P[8] lineages
have been identified, although the identification of sub-genotypic lineages often occurs on
an ad hoc basis (Parra et al., 2005;Matthijnssens et al., 2010; Zeller et al., 2012).
It has previously been shown that routine vaccination with RotarixTM is associated
with an increased proportion of fully heterotypical G2P[4] rotaviruses (Gurgel et al., 2007;
Zeller et al., 2010;Matthijnssens et al., 2014). Less is known on whether the introduction
of RotarixTM also selects for certain lineages within the G1P[8] genotype and how this
effects the overall genetic diversity of G1P[8] strains. In general, rotavirus evolution is
poorly understood and is determined by the accumulation of point mutations over time
and by reassortment events. The accumulation of point mutations results in genetic and
antigenic drift, whereas reassortment of gene segments allows for sudden adaptations
to altering selection pressures, probably playing an important role in viral evolution and
the generation of genetic diversity. Gene reassortment is not a random process and is re-
stricted by structural and functional viral protein-protein interactions and host specificity.
In humans, this is reflected in the existence of only two major genotype constellations
(Matthijnssens & Van Ranst, 2012). Therefore, viral fitness is most often maintained or
increased when a gene reassortment occurs among gene segments belonging to the same
(lineages of a) genotype. Precisely how often reassortment occurs in human rotaviruses,
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and what factors are involved, is poorly understood as many surveillance efforts tend to
primarily focus on the VP7 and VP4 gene segments (Iturriza-Gómara et al., 2011;Mwenda
et al., 2014).
Large scale comparative studies of Wa-like rotaviruses in the United States revealed
frequent intra-genogroup reassortment, but no inter-genogroup reassortment was ob-
served (McDonald et al., 2009;McDonald et al., 2011;McDonald et al., 2012). In contrast,
persistent genotype constellations were also observed to circulate in multiple seasons,
suggesting that even within a single genotype constellation preferred constellations
may be present. However, none of these studies specifically investigated the effect of
vaccine introduction on the intra-genotype dynamics of commonly circulating Wa-like
strains. Previously, we have reported the G1P[8] strain diversity in Belgium and Australia,
and showed the existence of unique subclusters that were present only after vaccine
introduction (Zeller et al., 2015). In this study we investigate 70 Belgian G1P[8] strains
in relationship with the RotarixTM vaccine. This allowed us to analyze how circulating
G1P[8] strains collected before and after vaccination relate to the RotarixTM vaccine
strain, and will contribute to our understanding of the impact of vaccination on the
genetic diversity of rotaviruses, particularly G1P[8] strains.
METHODS
Sample collection and sequencing of wild-type G1P[8] rotaviruses
In total 70 G1P[8] RVA strains were selected based on their phylogenetic clustering of
VP7 in such a way that the selection reflected the genetic diversity of G1P[8] strains
in Belgium. For each sample approximately 50 mg of collected feces was resuspended
in 500 µl PBS and viral RNA was subsequently extracted with the Qiagen Viral RNA
minikit (Qiagen) according to the manufacturer’s instructions. In total 100 µl of viral
RNA was sent to the J. Craig Venter Institute for RT-PCR and sequencing in a high-
throughput fashion as described previously (McDonald et al., 2009; Zeller et al., 2015). A
RotarixTM G1P[8] vaccine strain was commercially obtained in Belgium to compare the
vaccine strain with circulating RVAs in Belgium, and reconstituted according to manu-
facturer’s recommendations (lot number: A41CB052A). Viral RNA was extracted with
the Qiagen Viral RNA minikit (Qiagen) according to manufacturer’s instructions and
subsequently the VP1-VP3, VP6 and NSP1-NSP5 gene segments were amplified using the
primers listed in Table S1 with a one-step RT-PCR kit (Qiagen). The nucleotide sequences
of RotarixTM VP7 and VP4 gene segments have been determined previously (Zeller et
al., 2012). The obtained amplicons were subsequently pooled in a ratio dependent on
the length of each gene segment and sequenced using 454TM GS-FLX pyrosequencing as
previously described (Heylen et al., 2015). Obtained reads were mapped against G1P[8]
reference strain Wa using MIRA 3.4 (Chevreux et al., 2004) and assemblies were visually
inspected in Tablet (Milne et al., 2013). Subsequently the consensus sequences for 9
gene segments of RotarixTM were determined, used for further analysis and deposited in
GenBank under accession numbers: KX954616– KX954624.
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Nucleotide sequence analysis
The genotypes for each of the eleven gene segments were determined using the online
rotavirus genotyping tool, RotaC (http://rotac.regatools.be) (Maes et al., 2009). Sequences
were aligned and the most optimal nucleotide substitution model was determined in
Mega 5 (Tamura et al., 2011). Maximum likelihood phylogenetic tree construction was
performed using the GTR substitution model allowing for a gamma-distributed rate
variation among sites with 500 bootstrap replicates. These maximum likelihood trees were
subsequently used to automatically detect clusters with the CTree heuristic cluster finding
algorithm using the most sensitive parameters (Archer & Robertson, 2007). This method
takes into account the overall genetic diversity of a gene segment when partitioning the
sequence data into clusters. Matlab was used to calculate and plot genetic differences
between RotarixTM and circulating G1P[8] strains. Statistical differences in prevalence
of lineages circulating before and after vaccine introduction were determined by Fisher’s
exact test.
RESULTS
Viral dataset
Belgian G1P[8] stool samples were collected between 1999 and 2010 from hospitalized
children with acute gastroenteritis. Until the 2006–2007 season, when no vaccines were
available in Belgium, G1P[8] was the most prevalent genotype. After the 2006–2007
season, when the RotarixTM vaccine was introduced, G2P[4] was the most prevalent
genotype and G1P[8] the second most prevalent (Zeller et al., 2010). In total 36 G1P[8]
strains were collected before vaccine introduction and 34 were collected after vaccine
introduction according to the selection criteria described above. For every gene segment
of all 70 Belgian G1P[8] strains, the genotype was determined using the RotaC genotyping
tool and a complete Wa-like genotype constellation for all 70 Belgian G1P[8] strains was
observed.
Belgian G1P[8] rotaviruses display frequent intra-genotypic
reassortment and persistent cluster constellations
To determine intra-genotypic variation and reassortment patterns the 70 G1P[8] strains
together with the RotarixTM vaccine strain were used for maximum likelihood phylo-
genetic tree reconstruction. For each gene segment phylogenetic clusters were assigned
using the automated cluster finding algorithm implemented in Ctree (Archer & Robertson,
2007) (Fig. 1 and Fig. S1). Most gene segments were divided into two clusters (VP7, VP1,
VP2, VP3, NSP1 and NSP5), whereas other gene segments were partitioned in three
(VP4, VP6 and NSP4) or four clusters (NSP2 and NSP3). The genetic distance be-
tween clusters was largest for NSP1, NSP2, VP4 and VP6. One Belgian G1P[8] strain,
RVA/Human-wt/BEL/BE00048/2009/G1P[8], was almost identical to RotarixTM for
every gene segment. Together with strain BE00048, the RotarixTM vaccine strain was
found in similar clusters as Belgian G1P[8] strains, except for VP6 and NSP2, for which
RotarixTM and BE00048 constituted separate clusters.
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Figure 1 Maximum likelihood phylogenetic trees for eleven gene segments of 70 Belgian G1P[8] rotaviruses and the RotarixTM vaccine strain,
which is indicated by a black star. All trees are drawn to the same scale and phylogenetic trees were divided in one to four clusters colored in green,
blue, purple and orange, respectively.
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The identification of clusters within each gene segment allowed us to determine the
cluster constellation for each of the Belgian G1P[8] rotaviruses and the RotarixTM vaccine
strain (Fig. 2A). In every rotavirus season G1P[8] rotaviruses with different cluster
constellations were co-circulating. This was the case for rotavirus seasons before vaccine
introduction as well as after vaccine introduction. During the study period also the
introduction of novel G1P[8] clusters was observed such as the purple clusters in NSP2,
NSP3 and NSP4 (Fig. 2A). Most of them were only minor variants and tended to circulate
for only a limited number of seasons before disappearing and re-emerging in later
rotavirus seasons. For all gene segments there were only two major clusters (indicated in
green and blue) that were circulating throughout the whole study period.
When the 70 G1P[8] strains were ordered according to their cluster constellation
similarity, 30 different cluster constellations were identified (Fig. 2B). However, only nine
cluster constellations (I–IX) were found to persistently circulate in multiple rotavirus
seasons and these ranged in size from two strains (cluster constellation III, VI and VII)
to up to twelve strains (cluster constellation I). The longest circulating clusters, cluster
I and V, were circulating in seven and four rotavirus seasons, respectively. Cluster I
was first observed in 1999–2000, reappeared in 2005–2006 and was found in all subse-
quent rotaviruses seasons, whereas cluster V was detected in 2004–2005, 2005–2006,
2007–2008 and 2009–2010. Other persistent clusters consisted of fewer strains and were
either found in successive rotavirus seasons (cluster II and III) or were found multiple
rotavirus seasons apart (cluster IV, VI, VII, VIII and IX).
The RotarixTM vaccine strain possessed a cluster constellation that was not found
in other circulating Belgian G1P[8] strains, except for BE00048, which possessed an
identical cluster constellation to that of RotarixTM and was obtained from a child that
was vaccinated approximately 10 weeks before the sample was collected and was almost
certainly vaccine-derived (Zeller et al., 2012). The RotarixTM and BE00048 cluster
constellations were found to possess unique clusters for the VP6 and NSP2 gene segment
(Fig. 2; purple and orange clusters for VP6 and NSP2, respectively). Although BE00048
and RotarixTM contained similar cluster constellations, 18 nucleotide differences were
observed (Table 1). These differences were found in the VP7, VP4, VP6, VP1, VP3, NSP1,
NSP4 and NSP5 gene segments and except for two nucleotide changes in VP4 and NSP1,
they all resulted in amino acid changes. However, base calling was ambiguous at many
of these nucleotide positions, indicating that both the original nucleotide of the vaccine
strain as well as the novel variant were present at a particular position.
G1P[8] clusters containing the vaccine strain were less prevalent
after vaccine introduction
For each gene segment the prevalence of different clusters before and after vaccine
introduction was determined (Fig. 3). Statistically significant differences in prevalence
before and after vaccine introduction were observed in the NSP1 (40.6%), NSP5 (32.6%),
VP7 (28.8%) and VP6 (30.1%) gene segments. For these four gene segments, blue colored
clusters became less prevalent after vaccine introduction when compared to seasons
before vaccine introduction. For nine out of eleven gene segments, the RotarixTM vaccine
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Figure 2 Cluster constellations of 70 Belgian G1P[8] rotaviruses and the RotarixTM vaccine strain.
For every strain, each gene segment is assigned in a cluster indicated by green, blue, purple or orange. (A)
Cluster constellations chronologically ordered. The vaccine introduction is indicated by a dashed line. (B)
Cluster constellations ordered by similarity. Persistent cluster constellations over multiple seasons are in-
dicated by roman numerals.
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Table 1 Nucleotide and amino acid differences between the RotarixTM vaccine strain and
RVA/Human-wt/BE00048/2009/G1P[8].
Gene segment Nucleotide change Amino acid change
VP7 T605C M202T
VP4 T501W F167?
C1175M A392?
C1515T –
VP6 T632Y I211?
G634R V212?
VP1 T90Y S30?
G1426A V476I
VP3 C319T H107Y
T937C S313P
C1838T A613V
NSP1 A15G –
NSP4 G109A A37T
T125K V42?
T128Y L43?
T137Y L46?
NSP5 G273R M91?
G274T D92Y
strain belonged to the cluster that was relatively less prevalent after vaccine introduction.
For VP6 and NSP2 the RotarixTM vaccine strain belonged to a unique cluster and no
changes in relative prevalence could be determined.
To gain a more detailed insight in how closely Belgian G1P[8] rotaviruses were related
to the RotarixTM vaccine strain the genetic distance of 70 Belgian G1P[8] strains to
RotarixTM was determined for every gene segment (Fig. 4A). At the nucleotide level,
large differences were observed between the different gene segments. The maximum
genetic distance to RotarixTM was largest for NSP1 (17.0%), followed by NSP2 (12.1%)
and VP6 (11.3%). NSP3, VP1 and VP7 were most closely related to RotarixTM with a
maximum distance of 4.7%, 5.3% and 6.5%, respectively. For most gene segments the
genetic distance to RotarixTM was characterized by groups of strains with a relatively low
genetic distance (generally less than 5 percent) and groups of strains with a higher genetic
distance to RotarixTM, reflecting the different clusters as defined previously. For the VP6
and NSP2 gene segments, all circulating G1P[8] strains were relatively distantly related
to the vaccine strain, the most closely related strain to RotarixTM were 8.6% and 9.4%
different, respectively.
In general, the genetic distances to the RotarixTM vaccine strain were lower at the
amino acid level than at the nucleotide level with exception of NSP1, for which the
maximum genetic diversity increased from 17.0% at the nucleotide level to 18.5% at the
amino acid level (Fig. 4B). The VP1 gene segment showed the highest similarity between
RotarixTM and circulating Belgian G1P[8] strains at the amino acid level (1.7%). The
VP6 and NSP2 gene segment, which were relatively distantly related to RotarixTM at the
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Figure 3 Differences in relative prevalence of clusters before and after vaccine introduction. For ev-
ery gene segment the cluster containing RotarixTM is indicated with a red triangle. Statistical differences
were tested using Fisher’s exact test and the resulting p-value is shown on the right-hand side. Significant
p-values are indicated in bold face.
nucleotide level, were relatively closely related to the vaccine strain at the amino acid level
(3.0% and 5.4%, respectively) and 91.4% and 85.9% of all nucleotide differences with the
vaccine strain were synonymous, respectively.
DISCUSSION
Rotavirus vaccines have been introduced in many countries around the world (Patel et al.,
2012), but rotaviruses still remain an important cause of morbidity and mortality. Despite
this, our knowledge of their genetic diversity is still relatively limited compared to other
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Figure 4 Genetic distances between 70 Belgian G1P[8] rotavirus strains and the RotarixTM vaccine strain on the nucleotide level (A) and on the
amino acid level (B). RotarixTM is positioned in the center and each wild-type strain is represented with a filled circle. A higher genetic distance to
RotarixTM is indicated by a more outward position.
viruses such as influenza A virus, and has considerably hindered our understanding of
rotavirus genetic diversity and of how rotaviruses evolve between consecutive seasons.
In particularly, it is unknown what the impact of vaccine introductions are on rotavirus
evolution.
In the present study the effect of rotavirus vaccine introduction on circulating G1P[8]
rotaviruses was investigated. Previously, we have shown in a large comparative study
comprising Belgian and Australian RVA strains that gene segments probably have distinct
evolutionary histories and that unique phylogenetic subclusters were present after
vaccine introduction (Zeller et al., 2015). Here we show by using the same G1P[8] sample
collection that depending on the gene segment, substantial differences exist in comparison
with the RotarixTM vaccine strain and that non-RotarixTM clusters were more prevalent
after vaccine introduction.
G1P[8] is worldwide the most prevalent genotype and also in Belgium G1P[8] is one
of the few genotypes that was observed in all RVA seasons since rotavirus surveillance
started in 1999 (Zeller et al., 2010; Bányai et al., 2012). Rotavirus vaccination in Belgium
was introduced in 2006 and within two rotavirus seasons reached a high coverage of
approximately 85% (Zeller et al., 2010; Braeckman et al., 2011). Uniquely, our dataset
comprised rotavirus samples spanning six seasons before and four seasons after vaccine
introduction. Although only Wa-like genotypes were found, a relative high genetic
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diversity was observed at the subgenotype level. This diversity was present in all eleven
gene segments and was used to divide our dataset into clusters, revealing a high level of
reassortment among G1P[8] strains in Belgium. Previously, this was also shown in an
archival dataset containing 51 G3P[8] RVAs and in a contemporary dataset comprising
58 G1P[8], G3P[8] and G12P[8] strains (McDonald et al., 2009;McDonald et al., 2012).
These samples were collected in the USA in a period without any use of rotavirus
vaccines (McDonald et al., 2009) or in a transition period where the first season of sample
collection was before vaccine introduction while during the subsequent three seasons the
RotaTeqTM vaccine was widely used (McDonald et al., 2012). The findings of a high intra-
genotype reassortment frequency in combination with a significant genetic diversity in
this study, where a balanced set of G1P[8] samples before and after vaccine introduction
was obtained, suggests that this is a typical and apparently widely occurring characteristic
of rotavirus epidemiology over an extended period of time.
Until now it was unclear if universal mass vaccination with any of the two currently
available rotavirus vaccines will affect this pattern. In our dataset, however, we did find
the occurrence of intra-genotype reassortment both before and after vaccine introduction.
In contrast, we also found that certain subtypes were less prevalent after vaccine introduc-
tion and thereby reducing the possibility of intra-genotype reassortment. Because Belgium
is a relatively small country and in neighboring countries of Belgium rotavirus vaccines
are not widely used, a part of the genetic diversity within G1P[8] strains could also be
(re-)imported from neighboring countries. In our dataset, we found clear evidence of
emerging and reemerging minor variants as new clusters in for example NSP2 and NSP3.
Thus, continuing surveillance involving complete genome sequencing will be essential to
further expand our insights into these mechanisms.
Sequencing of the RotarixTM vaccine strain did not reveal any differences with the
RotarixTM vaccine sequences previously deposited in GenBank (accession numbers:
JX943604–JX943614) and showed that RotarixTM possessed a unique cluster constellation
which was not found in wild-type Belgian circulating G1P[8] strains. A potential cause
of this discrepancy could be the result of a 20–30 years difference in detection date
between the parent virus of the RotarixTM vaccine and circulating Belgian G1P[8]
rotaviruses. Previously, it was shown that this resulted in numerous amino acid changes
in antigenic sites of VP7 and VP4 (Zeller et al., 2012). Here we show that also for other
gene segments, especially VP6, VP2 and NSP2, a considerable genetic distance exists
between RotarixTM and circulating strains. As the precise mechanism of protection
afforded by RotarixTM is unknown, it is possible that further accumulation of point
mutations could over time result in a reduced effectiveness of the vaccine. However, the
unique cluster constellation also represents a significant benefit with regard to diagnostics
and detection of vaccine strains circulating in the human population. For example, a
11.3–12.1% nucleotide difference was observed between the VP6 and NSP2 gene segments
of circulating G1P[8] strains and their RotarixTM counterparts (Fig. 4A), turning them
into primary targets to discriminate between vaccine-derived and wild-type G1P[8]
rotaviruses. In fact, such an assay based on NSP2 was recently developed (Gautam et
al., 2014). Although these RotarixTM clusters were specific to the RotarixTM vaccine in
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Belgium, we cannot rule out that in different parts of the world the VP6 or NSP2 clusters
present in the vaccine are still in circulation. Furthermore, there are some indications that
the NSP2 gene segment might reassort relatively easily as inter-genogroup reassortment
has been more often reported for NSP2 than for many other gene segments including
VP6 (Matthijnssens & Van Ranst, 2012). Thus, even if a vaccine-derived NSP2 is detected,
sequencing additional gene segments is needed to exclude the possibility of reassortment
between vaccine and wild-type strains.
Our dataset comprised one strain (BE00048) that was most likely completely vaccine-
derived. Also in other countries vaccine-derived strains have been detected and even
horizontal transmission between siblings has been described (Rivera et al., 2011; Donato
et al., 2012; Hemming & Vesikari, 2012). Besides complete vaccine-derived strains, various
reports of reassortment between vaccine strains and circulating strains have also been
made (Bucardo et al., 2012; Rose et al., 2013). It is unclear on what scale this reassortment
occurs however, but no evidence for reassortment was found in our dataset despite the
extensive use of rotavirus vaccines in Belgium. The 18 nucleotide differences observed be-
tween BE00048 and the RotarixTM vaccine could be either the result of de novomutations
or positive selection of mutations already present in the vaccine. Unfortunately, we were
not able to confirm minor variants present in the vaccine as the sequence depth was low.
The selection of G1P[8] rotaviruses was mainly based on the phylogenetic diversity of
VP7. Although a lot of effort was made to reflect the existing genetic diversity we cannot
rule out certain biases. For example, no G1P[8] strains were selected from the 2003–2004
season even though G1P[8] strains were circulating in that particular season (Zeller et
al., 2010). Also, selecting a subset of samples implies that we may not have been able to
capture the full diversity of relatively rare subtypes within G1P[8]. However, the dataset
provides a good overview of the diversity and prevalence of the more common subtypes
(generally cluster I and cluster II) within G1P[8] rotaviruses circulating in Belgium.
To gain more insight in the long-term effects of vaccine introduction continued
surveillance is necessary, including complete genome sequencing of rotaviruses on a
routine basis. Sequence independent amplification in combination with next-generation
sequencing techniques seems a powerful, inexpensive and relatively effortless tool to
accomplish this.
ACKNOWLEDGEMENTS
We would like to thank Rebecca Halpin, Nadia Fedorova, Timothy Stockwell, and
Susmita Shrivastava for help with genome sequencing, assembly, and annotation.
ADDITIONAL INFORMATION AND DECLARATIONS
Funding
Mark Zeller was supported by the Institute for the Promotion of Innovation through
Science and Technology in Flanders (IWT Vlaanderen). This project has been funded
in part with federal funds from the National Institute of Allergy and Infectious Diseases,
Zeller et al. (2017), PeerJ, DOI 10.7717/peerj.2733 12/16
National Institutes of Health, Department of Health and Human Services under contract
number HHSN272200900007C. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Grant Disclosures
The following grant information was disclosed by the authors:
National Institute of Allergy and Infectious Diseases.
National Institutes of Health.
Department of Health and Human Services: HHSN272200900007C.
Competing Interests
JM serves as a consultant for GSK on the genetic stability of the rotavirus G1P[8] strain
(Rotarix) and safety aspects. Ewen Kirkness is an employee of Human Longevity, Inc.
Author Contributions
• Mark Zeller conceived and designed the experiments, analyzed the data, wrote the
paper, prepared figures and/or tables, reviewed drafts of the paper.
• Elisabeth Heylen conceived and designed the experiments, performed the experiments,
analyzed the data, wrote the paper, reviewed drafts of the paper.
• Sana Tamim and Sarah De Coster performed the experiments, reviewed drafts of the
paper.
• John K. McAllen, Ewen F. Kirkness and Asmik Akopov performed the experiments,
contributed reagents/materials/analysis tools, reviewed drafts of the paper.
• Marc Van Ranst conceived and designed the experiments, contributed reagents/materi-
als/analysis tools, wrote the paper, reviewed drafts of the paper.
• Jelle Matthijnssens conceived and designed the experiments, analyzed the data, wrote
the paper, reviewed drafts of the paper.
DNA Deposition
The following information was supplied regarding the deposition of DNA sequences:
Sequences were deposited in GenBank under accession numbers KX954616–KX954624.
Data Availability
The following information was supplied regarding data availability:
The raw data or code is included in the manuscript.
Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.
7717/peerj.2733#supplemental-information.
REFERENCES
Archer J, Robertson DL. 2007. CTree: comparison of clusters between phylogenetic trees
made easy. Journal of Gerontology 23:2952–2953.
Zeller et al. (2017), PeerJ, DOI 10.7717/peerj.2733 13/16
Bányai K, László B, Duque J, Steele AD, Nelson EAS, Gentsch JR, Parashar UD.
2012. Systematic review of regional and temporal trends in global rotavirus
strain diversity in the pre rotavirus vaccine era: insights for understanding the
impact of rotavirus vaccination programs. Vaccine 30(Suppl 1):A122–A130
DOI 10.1016/j.vaccine.2012.07.055.
Braeckman T, Van Herck K, Raes M, Vergison A, SabbeM, Van Damme P. 2011.
Rotavirus vaccines in Belgium: policy and impact. The Pediatric Infectious Disease
Journal 30:S21–S24 DOI 10.1097/INF.0b013e3181fefc51.
Bucardo F, Rippinger CM, Svensson L, Patton JT. 2012. Vaccine-derived NSP2 segment
in rotaviruses from vaccinated children with gastroenteritis in Nicaragua. Infection,
Genetics and Evolution 12:1282–1294 DOI 10.1016/j.meegid.2012.03.007.
Chevreux B, Pfisterer T, Drescher B, Driesel AJ, MüllerWEG,Wetter T, Suhai S. 2004.
Using the miraEST assembler for reliable and automated mRNA transcript assembly
and SNP detection in sequenced ESTs. Genome Research 14:1147–1159.
Donato CM, Ch’ng LS, Boniface KF, Crawford NW, Buttery JP, LyonM, Bishop RF,
Kirkwood CD. 2012. Identification of strains of RotaTeq rotavirus vaccine in infants
with gastroenteritis following routine vaccination. Journal of Infectious Diseases
206:377–383 DOI 10.1093/infdis/jis361.
Gautam R, EsonaMD,Mijatovic-Rustempasic S, Ian TamK, Gentsch JR, BowenMD.
2014. Real-time RT-PCR assays to differentiate wild-type group A rotavirus strains
from Rotarix( R©) and RotaTeq( R©) vaccine strains in stool samples. Human Vaccines
& Immunotherapeutics 10(3):767–777.
Gurgel RQ, Cuevas LE, Vieira SCF, Barros VCF, Fontes PB, Salustino EF, Nak-
agomi O, Nakagomi T, DoveW, Cunliffe N, Hart CA. 2007. Predominance of
rotavirus P[4]G2 in a vaccinated population, Brazil. Emerging Infectious Diseases
13:1571–1573 DOI 10.3201/eid1310.070412.
HemmingM, Vesikari T. 2012. Vaccine-derived human-bovine double reassortant
rotavirus in infants with acute gastroenteritis. The Pediatric Infectious Disease Journal
31(9):992–994 DOI 10.1097/INF.0b013e31825d611e.
Heylen E, Zeller M, Ciarlet M, Lawrence J, Steele D, Van Ranst M, Matthijnssens
J. 2015. Can a shared bovine backbone explain the high vaccine efficacy of
RotaTeqTM against African G8 rotaviruses? Scientific Reports 5:14658
DOI 10.1038/srep14658.
Iturriza-GómaraM, Dallman T, Bányai K, Böttiger B, Buesa J, Diedrich S, Fiore
L, Johansen K, KoopmansM, Korsun N, Koukou D, Kroneman A, László B,
LappalainenM,Maunula L, Marques AM,Matthijnssens J, Midgley S, Mladenova
Z, Nawaz S, Poljsak-Prijatelj M, Pothier P, Ruggeri FM, Sanchez-Fauquier A,
Steyer A, Sidaraviciute-Ivaskeviciene I, Syriopoulou V, Tran AN, Usonis V, Van
Ranst M, Rougemont DEA, Gray J. 2011. Rotavirus genotypes co-circulating in
Europe between 2006 and 2009 as determined by EuroRotaNet, a pan-European
collaborative strain surveillance network. Epidemiology and Infection 139:895–909
DOI 10.1017/S0950268810001810.
Zeller et al. (2017), PeerJ, DOI 10.7717/peerj.2733 14/16
Maes P, Matthijnssens J, RahmanM, Van Ranst M. 2009. RotaC: a web-based tool for
the complete genome classification of group A rotaviruses. BMCMicrobiology 9:238
DOI 10.1186/1471-2180-9-238.
Matthijnssens J, Ciarlet M, Heiman E, Arijs I, Delbeke T, McDonald SM, Palombo
EA, Iturriza-GómaraM,Maes P, Patton JT, RahmanM, Van Ranst M. 2008. Full
genome-based classification of rotaviruses reveals a common origin between human
Wa-Like and porcine rotavirus strains and human DS-1-like and bovine rotavirus
strains. Journal of Virology 82:3204–3219 DOI 10.1128/JVI.02257-07.
Matthijnssens J, Joelsson DB,Warakomski DJ, Zhou T, Mathis PK, VanMaanenM-
H, Ranheim TS, Ciarlet M. 2010.Molecular and biological characterization of
the 5 human-bovine rotavirus (WC3)-based reassortant strains of the pentavalent
rotavirus vaccine, RotaTeq. Virology 403:111–127 DOI 10.1016/j.virol.2010.04.004.
Matthijnssens J, Van Ranst M. 2012. Genotype constellation and evolution of
group A rotaviruses infecting humans. Current Opinion in Virology 2:426–433
DOI 10.1016/j.coviro.2012.04.007.
Matthijnssens J, Zeller M, Heylen E, De Coster S, Vercauteren J, Braeckman T, Van
Herck K, Meyer N, Pirc¸on J-Y, Soriano-GabarróM, AzouM, Capiau H, De Koster
J, Maernoudt A-S, Raes M, Verdonck L, Verghote M, Vergison A, Van Damme
P, Van Ranst M, The RotaBel study group. 2014.Higher proportion of G2P[4]
rotaviruses in vaccinated hospitalised cases compared to unvaccinated hospitalised
cases, despite high vaccine effectiveness against heterotypic G2P[4] rotaviruses.
Clinical Microbiology and Infection 20(10):O702–O710.
McDonald SM, Davis K, McAllen JK, Spiro DJ, Patton JT. 2011. Intra-genotypic
diversity of archival G4P[8] human rotaviruses fromWashington, DC. Infection,
Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics
in Infectious Diseases 11:1586–1594 DOI 10.1016/j.meegid.2011.05.023.
McDonald SM,Matthijnssens J, McAllen JK, Hine E, Overton L,Wang S, Lemey P,
Zeller M, Van Ranst M, Spiro DJ, Patton JT. 2009. Evolutionary dynamics of human
rotaviruses: balancing reassortment with preferred genome constellations. PLoS
Pathogens 5:e1000634 DOI 10.1371/journal.ppat.1000634.
McDonald SM,McKell AO, Rippinger CM,McAllen JK, Akopov A, Kirkness EF, Payne
DC, Edwards KM, Chappell JD, Patton JT. 2012. Diversity and relationships of
cocirculating modern human rotaviruses revealed using large-scale comparative
genomics. Journal of Virology 86:9148–9162 DOI 10.1128/JVI.01105-12.
Milne I, Stephen G, Bayer M, Cock PJA, Pritchard L, Cardle L, Shaw PD,Marshall D.
2013. Using Tablet for visual exploration of second-generation sequencing data.
Briefings in Bioinformatics 14:193–202 DOI 10.1093/bib/bbs012.
Mwenda JM, Tate JE, Parashar UD, Mihigo R, Agócs M, Serhan F, Nshimirimana
D. 2014. African rotavirus surveillance network: a brief overview. The Pediatric
Infectious Disease Journal 33(Suppl 1):S6–S8 DOI 10.1097/INF.0000000000000174.
Parra GI, Bok K, Martínez V, Russomando G, Gomez J. 2005.Molecular characteriza-
tion and genetic variation of the VP7 gene of human rotaviruses isolated in Paraguay.
Journal of Medical Virology 77:579–586 DOI 10.1002/jmv.20427.
Zeller et al. (2017), PeerJ, DOI 10.7717/peerj.2733 15/16
Patel MM, Glass R, Desai R, Tate JE, Parashar UD. 2012. Fulfilling the promise of
rotavirus vaccines: how far have we come since licensure? The Lancet Infectious
Diseases 12:561–570 DOI 10.1016/S1473-3099(12)70029-4.
Rivera L, Peña LM, Stainier I, Gillard P, Cheuvart B, Smolenov I, Ortega-Barria E,
Han HH. 2011.Horizontal transmission of a human rotavirus vaccine strain–
a randomized, placebo-controlled study in twins. Vaccine 29:9508–9513
DOI 10.1016/j.vaccine.2011.10.015.
Rose TL, Marques da Silva MF, GomézMM, Resque HR, Ichihara MY, Volotão E deM,
Leite JP. 2013. Evidence of vaccine-related reassortment of rotavirus, Brazil, 2008–
2010. Emerging Infectious Diseases 19:1843–1846 DOI 10.3201/eid1911.121407.
Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011.MEGA5:
molecular evolutionary genetics analysis using maximum likelihood, evolutionary
distance, and maximum parsimony methods.Molecular Biology and Evolution
28:2731–2739 DOI 10.1093/molbev/msq189.
Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD.WHO-
Coordinated Global Rotavirus Surveillance Network. 2012. 2008 estimate
of worldwide rotavirus-associated mortality in children younger than 5 years
before the introduction of universal rotavirus vaccination programmes: a sys-
tematic review and meta-analysis. The Lancet Infectious Diseases 12:136–141
DOI 10.1016/S1473-3099(11)70361-9.
Zeller M, Donato CM, Trovão NS, Cowley D, Heylen E, Donker NC, McAllen JK,
Akopov A, Kirkness EF, Lemey P, Van Ranst M, Matthijnssens J, Kirkwood CD.
2015. Genome-wide evolutionary analyses of G1P[8] strains isolated before and
after rotavirus vaccine introduction. Genome Biology and Evolution 7(9):2473–2483
DOI 10.1093/gbe/evv157.
Zeller M, Patton JT, Heylen E, De Coster S, Ciarlet M, Van Ranst M, Matthijnssens
J. 2012. Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes
between human rotaviruses circulating in Belgium and rotaviruses in rotarix and
RotaTeq. Journal of Clinical Microbiology 50:966–976 DOI 10.1128/JCM.05590-11.
Zeller M, RahmanM, Heylen E, De Coster S, De Vos S, Arijs I, Novo L, Verstappen N,
Van Ranst M, Matthijnssens J. 2010. Rotavirus incidence and genotype distribution
before and after national rotavirus vaccine introduction in Belgium. Vaccine
28:7507–7513 DOI 10.1016/j.vaccine.2010.09.004.
Zeller et al. (2017), PeerJ, DOI 10.7717/peerj.2733 16/16
